EU Accelerated Assessment Tracker: EMA To Fast Track Thalassemia Gene Therapy, New HIV Drug

Bluebird Bio’s LentiGlobin and Theratechnologies’ Trogarzo are both first of their kind treatments for transfusion-dependent β-thalassemia and HIV respectively.

PS1808_Racetrack_404954305_1200.jpg
Two new drugs could get to market faster in the EU • Source: Shutterstock

The European Medicines Agency has agreed to review two new investigational medicines under its accelerated assessment procedure.

The products are bluebird bio’s LentiGlobin gene therapy for the treatment of patients with transfusion-dependent β-thalassemia (TDT) and

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards